Pomerantz LLP Reminds Shareholders with Losses on their Investment in MoonLake Immunotherapeutics – MLTX

NEW YORK CITY, NY / ACCESS Newswire / December 15, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("Moonlake" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Moonlake and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.You have until December 15, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Moonlake securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.[Click here for information about joining the class action]On September 28, 2025, MoonLake reported disappointing results from its Phase 3 VELA trials evaluating the efficacy and safety of sonelokimab. One trial failed to meet its primary endpoint, while the other showed only modest gains versus placebo.Following this news, MoonLake's stock price fell $55.75 per share, or 89.93%, to close at $6.24 per share on September 29, 2025.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLPView the original press release on ACCESS Newswire